Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain

Simply Wall St.08-04

Aurinia Pharmaceuticals has delivered a 50.1% gain over the past three years, yet its valuation checks still point to the stock looking cheap on several fronts. Recent share price softness adds to the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656812725?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-04 11:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656812725","market":"hk","top_or_hot":-1,"title":"Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain","media":"Simply Wall St.","content":"<div>\n<p>Aurinia Pharmaceuticals has delivered a 50.1% gain over the past three years, yet its valuation checks still point to the stock looking cheap on several fronts. Recent share price softness adds to the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-stock-still-looks-cheap-despite\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-04 11:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-stock-still-looks-cheap-despite><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aurinia Pharmaceuticals has delivered a 50.1% gain over the past three years, yet its valuation checks still point to the stock looking cheap on several fronts. Recent share price softness adds to the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-stock-still-looks-cheap-despite\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TACU","symbol_name":"T. Rowe Price Active Core U.S. Equity ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-stock-still-looks-cheap-despite","article_id":"2656812725","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-stock-still-looks-cheap-despite","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2656812725","pubTimestamp":1785814111,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Aurinia Pharmaceuticals has delivered a 50.1% gain over the past three years, yet its valuation checks still point to the stock looking cheap on several fronts. Recent share price softness adds to the question of whether the current US$14.57 level is giving investors a discount or simply reflecting caution about the business.\n\nThe 50.1% return over three years suggests patient shareholders have already seen meaningful value created, which raises the bar for new buyers.\nFuture growth in...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TACU":"T. Rowe Price Active Core U.S. Equity ETF","CDIG":"City Different Investments Global Equity ETF","AUPH":"Aurinia Pharmaceuticals Inc","TSPA":"T. Rowe Price U.S. Equity Research ETF","BK4139":"生物科技"},"translate_title":"Aurinia Pharmaceuticals (AUPH) 股票尽管上涨 50%，但看起来仍然很便宜","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSPA":0.71,"CDIG":0.71,"TACU":0.71,"AUPH":1.5},"content_text":"Aurinia Pharmaceuticals has delivered a 50.1% gain over the past three years, yet its valuation checks still point to the stock looking cheap on several fronts. Recent share price softness adds to the question of whether the current US$14.57 level is giving investors a discount or simply reflecting caution about the business.  The 50.1% return over three years suggests patient shareholders have already seen meaningful value created, which raises the bar for new buyers. Future growth in Aurinia Pharmaceuticals' revenue and cash flow could support the current price, while any disappointment in execution or profitability may quickly influence what investors are willing to pay. Aurinia Pharmaceuticals scores highly on our broader checks, with 5 out of 6 valuation tests indicating that the shares are trading on the cheap side.  The issue now is whether Aurinia Pharmaceuticals' current valuation still leaves enough potential upside to compensate for the risks that come with the stock. Find out why Aurinia Pharmaceuticals' 24.5% return over the last year is lagging behind its peers. AdvertisementIs Aurinia Pharmaceuticals a Bargain on Earnings? The P/E multiple suits Aurinia Pharmaceuticals because the company is already generating earnings that can be compared directly with peers. Aurinia Pharmaceuticals currently trades on a P/E of about 6.3x, which is far below the Biotechs industry average of 17.1x and well under the peer group average of 39.4x. On simple market comparisons, investors are paying a much lower price for each dollar of earnings than is typical for the sector. A more tailored fair P/E ratio for Aurinia Pharmaceuticals, which factors in its growth, margins, size and risk profile, sits around 12.5x. That is still roughly double the current 6.3x level. The gap between the present P/E and this fair ratio suggests the market is applying a heavy discount to the stock despite the broader checks indicating value support. On the P/E multiple, Aurinia Pharmaceuticals stock currently screens as undervalued compared with both its fair ratio and sector benchmarks. NasdaqGM:AUPH P/E Ratio as at Aug 2026 See what the numbers say about this price — find out in our valuation breakdown. The Aurinia Pharmaceuticals Narrative: What Would Justify Today's Price? Simply Wall St Narratives for Aurinia Pharmaceuticals pick up where the valuation puzzle leaves off. They spell out which paths for revenue, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price. These narratives sit on the company’s Community page so you can see in plain terms what future is embedded in the current numbers and judge over time whether that story is still holding up. One of the top community narratives on Aurinia Pharmaceuticals: 31% undervalued \"Aritinercept is Aurinia Pharmaceuticals’ emerging autoimmune asset, built around a dual BAFF/APRIL inhibition mechanism intended to modulate B cell activity...\" Read one of the top narratives on Aurinia Pharmaceuticals Do you think there's more to the story for Aurinia Pharmaceuticals? Head over to our Community to see what others are saying! The Bottom Line Aurinia Pharmaceuticals still screens as undervalued on earnings, with the current P/E sitting well below both sector averages and a tailored fair ratio. That discount only helps if the company can deliver on the business outcomes that investors are implicitly building into those valuation checks. The key question now is whether earnings quality and growth can support a higher multiple, or whether the low valuation is the market pricing in execution and profitability risk. That tension between a cheap-looking P/E and the uncertainties around future delivery is likely to be the most important factor from here.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656812725","isCrawlerRequest":true}